Opinion|Videos|July 2, 2024
MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ensure coverage criteria for MS medications, and they also consider the factors that influence their decision-making process when selecting therapies for patients with relapsing multiple sclerosis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- The most recent guidelines for MS treatment are from 2018. Why is it important for an update to them?
- Payers often utilize not only pivotal trials when creating or updating coverage criteria for medications used to treat MS, but also other clinical studies and treatment guidelines. What role do guidelines, such as the MS Guidelines, play in updating or creating coverage criteria?
- Which patient factors weigh into your decision making for MS therapies for patients with relapsing multiple sclerosis?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Accountable Care: Not Just for the Healthiest Patients
2
Increased Risk of Recurrence in NSCLC Found After Preoperative PTNB
3
Novel Machine Learning Model Improves MASLD Detection in Type 2 Diabetes
4
Emerging Therapies for Managing Hidradenitis Suppurativa in Patients With Skin of Color
5
